Savara Inc
YB4P
Company Profile
Business description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Contact
1717 Langhorne Newtown Road
Suite 300
LanghornePA19047
USAT: +1 512 614-1848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.60 | 4.90 | 0.06% |
| CAC 40 | 7,734.90 | 3.52 | -0.05% |
| DAX 40 | 23,807.50 | 17.39 | 0.07% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,810.10 | 35.41 | 0.40% |
| HKSE | 24,069.94 | 151.47 | -0.63% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,785.90 | 23.42 | 0.06% |
| NZX 50 Index | 12,704.48 | 79.81 | -0.62% |
| S&P 500 | 6,227.42 | 29.41 | 0.47% |
| S&P/ASX 200 | 8,595.80 | 1.90 | -0.02% |
| SSE Composite Index | 3,461.15 | 6.36 | 0.18% |